277
Views
35
CrossRef citations to date
0
Altmetric
Review

CD28 co-stimulation in T-cell homeostasis: a recent perspective

, &
Pages 111-122 | Published online: 28 May 2015

References

  • ChenLFliesDBMolecular mechanisms of T cell co-stimulation and co-inhibitionNat Rev Immunol201313422724223470321
  • WaterhousePPenningerJMTimmsELymphoproliferative disorders with early lethality in mice deficient in Ctla-4Science19952709859887481803
  • SandersonKScotlandRLeePAutoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanomaJ Clin Oncol200523474175015613700
  • TaiXVan LaethemFSharpeAHSingerAInduction of autoimmune disease in CTLA-4−/− mice depends on a specific CD28 motif that is required for in vivo costimulationProc Natl Acad Sci U S A200710434137561376117702861
  • Sanchez-LockhartMKimMMillerJCutting edge: a role for inside-out signaling in TCR regulation of CD28 ligand bindingJ Immunol2011187115515551922068237
  • Sanchez-LockhartMRojasAVFettisMMT cell receptor signaling can directly enhance the avidity of CD28 ligand bindingPLoS One201492e8926324586641
  • CollinsAVBrodieDWGilbertRJThe interaction properties of costimulatory molecules revisitedImmunity200217220121012196291
  • WalkerLSSansomDMThe emerging role of CTLA4 as a cell-extrinsic regulator of T cell responsesNat Rev Immunol2011111285286322116087
  • DennehyKMEliasFNaSYFischerKDHunigTLuhderFMitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosomeJ Immunol200717831363137117237383
  • BoucherLMWiegmannKFüttererACD28 signals through acidic sphingomyelinaseJ Exp Med19951816205920687759998
  • MuellerNAvotaECollenburgLGrassmeHSchneider-SchauliesSNeutral sphingomyelinase in physiological and measles virus induced T cell suppressionPLoS Pathog20141012e100457425521388
  • O’ByrneDSansomDLack of costimulation by both sphingomyelinase and C2 ceramide in resting human T cellsImmunology2000100222523010886399
  • AbboushiNEl-HedAEl-AssaadWCeramide inhibits IL-2 production by preventing protein kinase C-dependent NF-kappaB activation: possible role in protein kinase Ctheta regulationJ Immunol200417353193320015322180
  • KumariSCuradoSMayyaVDustinMLT cell antigen receptor activation and actin cytoskeleton remodelingBiochim Biophys Acta20141838254655623680625
  • SaitoTYokosukaTHashimoto-TaneADynamic regulation of T cell activation and co-stimulation through TCR-microclustersFEBS Lett2010584244865487121110974
  • BoomerJSGreenJMAn enigmatic tail of CD28 signalingCold Spring Harb Perspect Biol201028a00243620534709
  • MuscoliniMCamperioCCapuanoCPhosphatidylinositol 4-phosphate 5-kinase alpha activation critically contributes to CD28-dependent signaling responsesJ Immunol2013190105279528623589613
  • FeskeSCalcium signalling in lymphocyte activation and diseaseNat Rev Immunol20077969070217703229
  • DennehyKMKerstanABischofAParkJHNaSYHunigTMitogenic signals through CD28 activate the protein kinase Ctheta-NF-kappaB pathway in primary peripheral T cellsInt Immunol200315565566312697665
  • EgenJGAllisonJPCytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strengthImmunity2002161233511825563
  • RuddCEThe reverse stop-signal model for CTLA4 functionNat Rev Immunol20088215316018219311
  • RuddCETaylorASchneiderHCD28 and CTLA-4 coreceptor expression and signal transductionImmunol Rev20092291122619426212
  • BachmannMFKohlerGEcabertBMakTWKopfMCutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomousJ Immunol199916331128113110415006
  • FriedlineRHBrownDSNguyenHCD4+ regulatory T cells require CTLA-4 for the maintenance of systemic toleranceJ Exp Med2009206242143419188497
  • RudolphMHebelKMiyamuraYMaverakisEBrunner-WeinzierlMCBlockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivoJ Immunol2011186105580558921478403
  • YaoSZhuYZhuGB7-h2 is a costimulatory ligand for CD28 in humanImmunity201134572974021530327
  • DiehnMAlizadehAARandoOJGenomic expression programs and the integration of the CD28 costimulatory signal in T cell activationProc Natl Acad Sci U S A20029918117961180112195013
  • RileyJLMaoMKobayashiSModulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptorsProc Natl Acad Sci U S A20029918117901179512195015
  • ApplemanLJBerezovskayaAGrassIBoussiotisVACD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progressionJ Immunol2000164114415110605005
  • MohapatraSAgrawalDPledgerWJp27Kip1 regulates T cell proliferationJ Biol Chem200127624219762198311297537
  • KovalevGIFranklinDSCoffieldVMXiongYSuLAn important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferationJ Immunol200116763285329211544316
  • FraserJDIrvingBACrabtreeGRWeissARegulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28Science199125149913133161846244
  • Granelli-PipernoANolanPNuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cellsJ Immunol19911478273427391655897
  • MillerJBakerCCookKTwo pathways of costimulation through CD28Immunol Res2009452–315917219214786
  • ShapiroVSTruittKEImbodenJBWeissACD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sitesMol Cell Biol1997177405140589199340
  • KimHPImbertJLeonardWJBoth integrated and differential regulation of components of the IL-2/IL-2 receptor systemCytokine Growth Factor Rev200617534936616911870
  • BoiseLHMinnAJNoelPJCD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XLImmunity19953187987621080
  • KhoshnanATindellCLauxIBaeDBennettBNelAEThe NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytesJ Immunol200016541743175410925251
  • KerstanAHunigTCutting edge: distinct TCR- and CD28-derived signals regulate CD95L, Bcl-xL, and the survival of primary T cellsJ Immunol200417231341134514734708
  • FrauwirthKARileyJLHarrisMHThe CD28 signaling pathway regulates glucose metabolismImmunity200216676977712121659
  • JacobsSRHermanCEMaciverNJGlucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathwaysJ Immunol200818074476448618354169
  • RathmellJCVander HeidenMGHarrisMHFrauwirthKAThompsonCBIn the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viabilityMol Cell20006368369211030347
  • RulifsonICSperlingAIFieldsPEFitchFWBluestoneJACD28 costimulation promotes the production of Th2 cytokinesJ Immunol199715826586658992981
  • Rodriguez-PalmeroMHaraTThumbsAHunigTTriggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivoEur J Immunol199929123914392410601999
  • OosterwegelMAMandelbrotDABoydSDThe role of CTLA-4 in regulating Th2 differentiationJ Immunol199916352634263910453003
  • AkbarANHensonSMAre senescence and exhaustion intertwined or unrelated processes that compromise immunity?Nat Rev Immunol201111428929521436838
  • WengNPAkbarANGoronzyJCD28(−) T cells: their role in the age-associated decline of immune functionTrends Immunol200930730631219540809
  • ThewissenMSomersVHellingsNFraussenJDamoiseauxJStinissenPCD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulationJ Immunol2007179106514652317982040
  • MartensPBGoronzyJJSchaidDWeyandCMExpansion of unusual CD4+ T cells in severe rheumatoid arthritisArthritis Rheum1997406110611149182921
  • WengNPLevineBLJuneCHHodesRJRegulated expression of telomerase activity in human T lymphocyte development and activationJ Exp Med19961836247124798676067
  • ParishSTWuJEEffrosRBSustained CD28 expression delays multiple features of replicative senescence in human CD8 T lymphocytesJ Clin Immunol201030679880520721608
  • StriogaMPasukonieneVCharaciejusDCD8+ CD28− and CD8+ CD57+ T cells and their role in health and diseaseImmunology20111341173221711350
  • SakaguchiSOnoMSetoguchiRFoxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune diseaseImmunol Rev200621282716903903
  • SoligoMCamperioCCaristiSCD28 costimulation regulates FOXP3 in a RelA/NF-kappaB-dependent mechanismEur J Immunol201141250351321268019
  • TangQHenriksenKJBodenEKCutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cellsJ Immunol200317173348335214500627
  • SalomonBLenschowDJRheeLB7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetesImmunity200012443144010795741
  • GogishviliTLuhderFGoebbelsSBeer-HammerSPfefferKHunigTCell-intrinsic and -extrinsic control of Treg-cell homeostasis and function revealed by induced CD28 deletionEur J Immunol201343118819323065717
  • LevineAGArveyAJinWRudenskyAYContinuous requirement for the TCR in regulatory T cell functionNat Immunol201415111070107825263123
  • GuoFIclozanCSuhWKAnasettiCYuXZCD28 controls differentiation of regulatory T cells from naive CD4 T cellsJ Immunol200818142285229118684917
  • LinsleyPSBradyWUrnesMGrosmaireLSDamleNKLedbetterJACTLA-4 is a second receptor for the B cell activation antigen B7J Exp Med199117435615691714933
  • LinsleyPSNadlerSGThe clinical utility of inhibiting CD28-mediated costimulationImmunol Rev2009229130732119426230
  • KnoerzerDBKarrRWSchwartzBDMengle-GawLJCollagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-IgJ Clin Invest19959629879937543497
  • BluestoneJASt ClairEWTurkaLACTLA4Ig: bridging the basic immunology with clinical applicationImmunity200624323323816546089
  • LarsenCPPearsonTCAdamsABRational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive propertiesAm J Transplant20055344345315707398
  • WojciechowskiDVincentiFBelatacept in kidney transplantationCurr Opin Organ Transplant201217664064723044530
  • KrummelMFSullivanTJAllisonJPSuperantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivoInt Immunol1996845195238671638
  • DenglerTJSzaboGSidoBProlonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantationTransplantation199967339239810030284
  • YuXZAlbertMHMartinPJAnasettiCCD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigensJ Clin Invest2004113111624163015173889
  • HunigTManipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodiesAdv Immunol20079511114817869612
  • PoirierNBlanchoGVanhoveBA more selective costimulatory blockade of the CD28-B7 pathwayTranspl Int201124121120964725
  • DennehyKMEliasFZeder-LutzGCutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responsesJ Immunol2006176105725572916670276
  • BeyersdorfNDingXBlankGDennehyKMKerkauTHunigTProtection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibodyBlood2008112104328433618780833
  • ZhangTFresnaySWeltyESelective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent mannerAm J Transplant20111181599160921749640
  • PoirierNMaryCDilekNPreclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent fab’ antibodyAm J Transplant201212102630264022759318
  • PoirierNAzimzadehAMZhangTInducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantationSci Transl Med201021717ra10
  • LeachDRKrummelMFAllisonJPEnhancement of antitumor immunity by CTLA-4 blockadeScience19962715256173417368596936
  • SeligerBMarincolaFMFerroneSAbkenHThe complex role of B7 molecules in tumor immunologyTrends Mol Med2008141255055918986838
  • BlankCUEnkATherapeutic use of anti-CTLA-4 antibodiesInt Immunol201527131025038057
  • SimpsonTRLiFMontalvo-OrtizWFc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaJ Exp Med201321091695171023897981
  • BulliardYJolicoeurRWindmanMActivating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodiesJ Exp Med201321091685169323897982
  • SelbyMJEngelhardtJJQuigleyMAnti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cellsCancer Immunol Res201311324224777248
  • RibasAClinical development of the anti-CTLA-4 antibody tremelimumabSemin Oncol201037545045421074059
  • BoasbergPHamidOO’DaySIpilimumab: unleashing the power of the immune system through CTLA-4 blockadeSemin Oncol201037544044921074058
  • RibasAKeffordRMarshallMAPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaJ Clin Oncol201331561662223295794
  • WolchokJDHodiFSWeberJSDevelopment of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanomaAnn N Y Acad Sci2013129111323772560
  • BruhnsPProperties of mouse and human IgG receptors and their contribution to disease modelsBlood2012119245640564922535666
  • WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
  • BischofAHaraTLinC-HBeyersAHünigTAutonomous induction of proliferation, JNK and NFkB activation in primary resting T-cells by mobilized CD28Eur J Immunol20003087688210741404
  • LühderFHuangYDennehyKMTopological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonistsJ Exp Med2003197895596612707299
  • EvansEJEsnoufRMManso-SanchoRCrystal structure of a soluble CD28-Fab complexNat Immunol20056327127915696168
  • LevinSEZhangCKadlecekTAShokatKMWeissAInhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signalingJ Biol Chem200828322154191543018378687
  • RömerPSBerrSAvotaEPreculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412Blood2011118266772678221931118
  • AnderssonJStefanovaIStephensGLShevachEMCD4+CD25+ regulatory T cells are activated in vivo by recognition of selfInt Immunol200719455756617369190
  • BeyersdorfNGauppSBalbachKSelective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitisJ Exp Med2005202344545516061730
  • TabaresPBerrSRömerPSHuman regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08Eur J Immunol20144441225123624374661
  • WeiratherJHofmannUDBeyersdorfNFoxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiationCirc Res20141151556724786398
  • NaSYMracskoELieszAHunigTVeltkampRAmplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in miceStroke201546121222025378432
  • SuntharalingamGPerryMRWardSCytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412N Engl J Med2006355101018102816908486
  • EastwoodDFindlayLPooleSMonoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cellsBr J Pharmacol2010161351252620880392
  • StefanovaIDorfmanJRGermainRNSelf-recognition promotes the foreign antigen sensitivity of naive T lymphocytesNature2002420691442943412459785
  • TyrsinDNew Mechanism of Action for Treatment of Autoimmune Diseases2014 [cited 23, January, 2015]. Available from: http://viewer.zmags.com/publication/a12191bd#/a12191bd/14.
  • SeahSGCarringtonEMNgWCUnlike CD4+ T-cell help, CD28 costimulation is necessary for effective primary CD8+ T-cell influenza-specific immunityEur J Immunol20124271744175422585421
  • DolfiDVDuttaguptaPABoesteanuACDendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivoJ Immunol201118684599460821389258